descriptive
Analysis v1
20
0
Stopping tesamorelin causes the positive effects to go away in people with HIV-related body changes. This finding is from the abstract summary - full study details were not available
Scientific Claim
Discontinuing tesamorelin treatment is associated with loss of benefits in HIV-1-infected patients with lipodystrophy.
Original Statement
“these benefits cease if treatment is discontinued”
Evidence Quality Assessment
Claim Status
overstated
Study Design Support
Design cannot support claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The abstract uses 'cease' which implies causation, but study design is unknown, so 'associated with' is appropriate.
Evidence from Studies
Supporting (1)
20
20
Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy
Case-Control Study
Human
2011 JanContradicting (0)
0
No contradicting evidence found